Progyny Inc. (PGNY)
21.96
-0.38 (-1.70%)
At close: Apr 14, 2025, 12:58 PM
-1.70% (1D)
| Bid | 21.94 |
| Market Cap | 1.88B |
| Revenue (ttm) | 1.17B |
| Net Income (ttm) | 54.34M |
| EPS (ttm) | 0.57 |
| PE Ratio (ttm) | 38.53 |
| Forward PE | 14.57 |
| Analyst | Hold |
| Ask | 22.1 |
| Volume | 250,276 |
| Avg. Volume (20D) | 1,807,045 |
| Open | 22.81 |
| Previous Close | 22.34 |
| Day's Range | 21.95 - 22.81 |
| 52-Week Range | 13.39 - 34.40 |
| Beta | 1.33 |
About PGNY
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the me...
Sector Healthcare
IPO Date Oct 25, 2019
Employees 675
Stock Exchange NASDAQ
Ticker Symbol PGNY
Website https://www.progyny.com
Analyst Forecast
According to 11 analyst ratings, the average rating for PGNY stock is "Hold." The 12-month stock price forecast is $23, which is an increase of 4.74% from the latest price.
Stock ForecastsNext Earnings Release
Progyny Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-0.52%
Progyny shares are trading higher after the compan...
Unlock content with
Pro Subscription
5 months ago
-19.09%
Progyny share shares are trading lower after the company reported worse-than-expected Q3 sales results and issued Q4 and FY24 revenue guidance below estimates.
